


11-24-03

1642
Image



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Anderson, et al.

EXAMINER: James Martinell

SERIAL NUMBER: 10/037,417

ART UNIT: 1646

FILING: DATE: October 26, 2001

FOR: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND
METHODS OF USING THE SAME

Mail Stop IDS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (4 page) in duplicate;
3. Copies of Cited references B1- B4 , and C146-C149 and;
4. Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (203) 974-6303, New Haven, Connecticut.

Respectfully submitted,

Date: November 21, 2003


George Yahwak, Reg. No. 26,824
c/o CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303
Fax: (203) 401-3351



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Anderson, et al.

EXAMINER: Not Yet Assigned

SERIAL NUMBER: 10/055,569

ART UNIT: 1646

FILING DATE: October 26, 2001

FOR: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND
METHODS OF USING THE SAME

Mail Stop IDS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents attached modified Form PTO-1449.

This Supplemental Information Disclosure Statement is being filed with in three months of the mailing date of the International Report of PCT/US/01/50925 Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, or that more relevant information

does not exist; and (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The order of presentation of the references should not be constructed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, as a result of this submission to Deposit Account No. 502648, Reference No. 21402-191 (Cura 491).

Respectfully submitted,



Date: November 21, 2003

George Yahwak, Reg. No. 26,824
c/o CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303
Fax: (203) 401-3351

Date of Deposit: _____

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/055,569
Filing Date	10/26/2001
First Named Inventor	Anderson, et al.
Group Art Unit	1646
Examiner Name	Not yet Assigned
Attorney Docket Number	21402-191 Cura 491

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1						

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	DE	100 31 932	Basf AG,	01/10/2002		x
	B2	WO	99/47540	Human Genome Sciences, Inc.	09/23/199	x	
	B3	WO	00/55173	Human Genome Sciences, Inc.	09/21/2000	x	
	B4	WO	01/83782	Sugen, Inc.	11/08/2001	x	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C146	Dear, T. N., N. T. Meier, et al. (2000). "Gene structure, chromosomal localization, and expression pattern of Capn12, a new member of the calpain large subunit gene family." Genomics 68(2): 152-60.
	C147	Klein, R. D., Q. Gu, et al. (1996). "Selection for genes encoding secreted proteins and receptors." Proc Natl Acad Sci U S A 93(14): 7108-13.
	C148	Tremblay, L. O. and A. Herscovics (1999). "Cloning and expression of a specific human alpha 1,2-mannosidase that trims Man9GlcNAc2 to Man8GlcNAc2 isomer B during N-glycan biosynthesis." Glycobiology 9(10): 1073-8.
	C149	International Search Report of PCT/US01/50925 mailed September 4, 2003.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Anderson, et al.

EXAMINER: Not Yet Assigned

SERIAL NUMBER: 10/055,569

ART UNIT: 1646

FILING DATE: October 26, 2001

FOR: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND
METHODS OF USING THE SAME

Mail Stop IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents attached modified Form PTO-1449.

This Supplemental Information Disclosure Statement is being filed with in three months of the mailing date of the International Report of PCT/US/01/50925 Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, or that more relevant information

does not exist; and (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The order of presentation of the references should not be constructed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, as a result of this submission to Deposit Account No. 502648, Reference No. 21402-191 (Cura 491).

Respectfully submitted,



Date: November 21, 2003

George Yahwak, Reg. No. 26,824
c/o CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303
Fax: (203) 401-3351

Date of Deposit: _____

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/055,569
	Filing Date	10/26/2001
	First Named Inventor	Anderson, et al.
	Group Art Unit	1646
	Examiner Name	Not yet Assigned
	Attorney Docket Number	21402-191 Cura 491

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1						

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	DE 100 31 932	Basf AG,	01/10/2002	x
	B2	WO 99/47540	Human Genome Sciences, Inc.	09/23/199	x
	B3	WO 00/55173	Human Genome Sciences, Inc.	09/21/2000	x
	B4	WO 01/83782	Sugen, Inc.	11/08/2001	x

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C146	Dear, T. N., N. T. Meier, et al. (2000). "Gene structure, chromosomal localization, and expression pattern of Capn12, a new member of the calpain large subunit gene family." Genomics 68(2): 152-60.
	C147	Klein, R. D., Q. Gu, et al. (1996). "Selection for genes encoding secreted proteins and receptors." Proc Natl Acad Sci U S A 93(14): 7108-13.
	C148	Tremblay, L. O. and A. Herscovics (1999). "Cloning and expression of a specific human alpha 1,2-mannosidase that trims Man9GlcNAc2 to Man8GlcNAc2 isomer B during N-glycan biosynthesis." Glycobiology 9(10): 1073-8.
	C149	International Search Report of PCT/US01/50925 mailed September 4, 2003.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.